the pathway might be involed in the pathogenesis of FEVR [5] [6] [7] .
Anti-VEGF therapy was tried for FEVR in a few reports and was found to be effective [8] [9] [10] . Lucentis (Ranubizumab, Novatis
Company) was used in our study for inhibation of retinal neovascular activities as primary or combined therapy in FEVR of stage 2 or greater.
SUBJECTS AND METHODS
Retrospective, non-controlled clinical study. Intravitreal injection of ranubizumab was performed 2-3 mm away from limbus. Dosage of injection was 0.5 mg (0.05 mL) ranubizumab for adult patient and 0.25 mg (0.025 mL) for children (age below 18 years old). All patients were examined on the following day and 1mo after injection, then followed monthly to determine if the vascular changes were stable or further treatments needed.
RESULTS
The enrolled patients' data at baseline was listed in Table 1 . Table 2 . Anti-VEGF therapy has become the primary treatment of retinal neovascular problems such as wet age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. It has been found to be able to reduce retinal vascular permeability and reduction of exudate. There have been a number of reports of anti-VEGF for pediatric retinal diseases like Coat's disease and retinopathy of prematurity [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Reports indicated that Wnt-receptor/β-catenin pathway was related with retinal formation and regulations of VEGF expression. Mutation of protein that modulates the pathway might be involed in the pathogenesis of FEVR [5] [6] [7] . Anti-VEGF therapy was tried for FEVR in a few reports and was found to be effective [8] [9] [10] .
In our study, the IVR was used as a primary or combined Vision in the most of the eyes with IVR had remained stable or improved in our study. Similar effect of anti-VEGF for FEVR was reported by Quiram et al [8] .
Complications of IVR may include vitreous hemorrhage, retinal breaks and detachment, endothphalmitis and uncertain systemic side effects. In our study, neither ocular nor systemic side effects were recorded, implying that IVR for FEVR may be a safe treatment as recongnized in wet AMD treatment.
In general, our study has shown that IVR may be an effective modality in the treatment of FEVR either as the primary or as an ajunct to the conventional therapies. The long term effect and safty of IVR still need further research. 
